Symrise Partners with HBC to Expand Health Portfolio with Sustainable Marine Ingredients

Symrise Partners with HBC to Expand Health Portfolio with Sustainable Marine Ingredients

(IN BRIEF) Symrise has formed a strategic partnership with HBC, a Norwegian company specializing in marine-based ingredients from Atlantic salmon. This collaboration will enhance Symrise’s health category with clinically proven ingredients for human health and pet nutrition. Together, they will advance product development and leverage Symrise’s global reach to boost market access.

(PRESS RELEASE) HOLZMINDEN, 21-Feb-2025 — /EuropaWire/ — Symrise AG has entered into a strategic alliance with HBC, a Norwegian leader in the production of sustainable, human-grade marine proteins, collagens, and oils derived from Norwegian Atlantic salmon. This partnership marks an exciting expansion of Symrise’s presence in the health sector, introducing clinically validated marine ingredients into its portfolio to support the growth of human health and pet nutrition markets.

HBC’s commitment to sustainable growth and innovation is evident in its ambitious plans to transform its Berkak facility into a state-of-the-art enzymatic hydrolysis plant, set to triple the company’s current production capacity. Symrise and HBC will also explore opportunities for new product developments, utilizing Symrise’s go-to-market capabilities to promote HBC’s offerings on a global scale.

Dr. Jean-Yves Parisot, CEO of Symrise AG, emphasized the alignment of the partnership with Symrise’s “One Care” journey and the company’s focus on marine-based solutions. “HBC’s investment in clinical studies and their proven benefits in areas such as metabolic health, immune health, gut health, and mobility sets them apart. This partnership aligns with our goal to accelerate growth in health and explore the vast potential of the oceans through our Global Marine Platform,” he said.

Sustainability is a core value for HBC, and the company’s innovative technology upcycles salmon offcuts into bioactive ingredients with demonstrated health benefits. Through this collaboration, Symrise and HBC aim to enhance public awareness of the benefits of marine ingredients and position HBC as a global leader in science-driven marine nutrition.

Jon Olav Odegard, CEO of HBC, commented on the importance of the partnership: “Symrise has already been an invaluable partner, and this expanded collaboration will help us scale our operations and access new markets. The human health and premium pet sectors are growing rapidly, and with Symrise’s market presence, we are well-positioned to lead the science-led marine nutrition segment.”

About Hofseth BioCare ASA (HBC):

Hofseth BioCare is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full traceability. It upcycles the side streams of the salmon industry by taking fresh filleted salmon and converting it from a waste product into ingredients to improve human and pet health. These ingredients are ProGo®, a mix of bioactive peptides and collagen, OmeGo®, a whole salmon oil, with all the fatty acid fractions contained in fish, and CalGo® / NT-II® salmon bone powder containing calcium hydroxyapatite and undenatured collagen for bone and joint health. HBC places scientific evidence at the forefront which has led to important academic partnerships and the identification of unique health benefits. This includes the demonstration of improved iron metabolism by boosting the body’s ability to take up and use iron resulting in increased energy and vitality with ProGo® as well as the activation of the GLP-1 receptor with fat reduction in overweight adults. OmeGo® has shown important immune health benefits including recovery from viral infection and improved respiratory health and sleep in adults troubled by particulate matter pollution. Finally, CalGo® has shown both bone and joint health benefits to support healthy ageing and active lifestyles. This work has also resulted in the granting of a number of patents protecting these discoveries. It has also led to the discovery of potential therapeutics and HBC has spun out a biotech-focused company, HBC Immunology (HBCI). HBCI has raised external finance, and the lead program is in prostate cancer followed by ovarian cancer. A separate molecule is targeted as an oral, steroid-sparing therapy for asthma.

About Symrise:

Symrise is a global supplier of fragrances, flavors, food, nutrition and cosmetic ingredients. Its clients include manufacturers of perfumes, cosmetics, food and beverages, pharmaceuticals and producers of
nutritional supplements and pet food. Its sales of around €5billion in the 2024 fiscal year make Symrise a leading global provider. Headquartered in Holzminden, Germany, the Group is represented by more than 100 locations in Europe, Africa, the Middle East, Asia, North and Latin America. Symrise works with its clients to develop new ideas and market-ready concepts for products that form an integral part of everyday life. Economic success and corporate
responsibility are inextricably linked as part of this process. Symrise – always inspiring more …

www.symrise.com

Media Contacts:
Bernhard Kott
Phone: +49 (0)5531 90-1721
Email: bernhard.kott@symrise.com

Investor Contact:
Rene Weinberg
Phone: +49 (0)5531 90-1879
Email: rene.weinberg@symrise.com

SOURCE: Symrise